510(k) Report

510(k) · Cleared

Cleared

Spectralis HRA+OCT and variants with High Magnification Module

K182569510(k) SpecialCleared Oct 18, 201830-day reviewClass II21 CFR 886.1570

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Heidelberg Engineering GmbH · OBO Tomography, Optical Coherence

Cleared on Oct 18, 2018 as substantially equivalent to K181594 (Heidelberg Engineering GmbH, 2018) after a 30-day review. Its family tree reaches back 9 generations to 2002. 7 later devices descend from it.

Decided
Oct 18, 2018
Review
30 days
Class
Class II
Product code
OBO
Recalls
None
Predicates
1

Its longest line of descent runs back 9 generations to K012727 (2002). 26 ancestors in all, the oldest K946058 (1995). 7 later devices descend from it, 1 citing it directly.

Other ancestors, by year clearedDescendants, by year cleared 2017: 1 other ancestor2016: 1 other ancestor2012: 1 other ancestor2010: 1 other ancestor2006: 3 other ancestors2005: 1 other ancestor2004: 2 other ancestors2002: 2 other ancestors2003: 1 other ancestor2001: 1 other ancestor1998: 1 other ancestor1995: 2 other ancestors2019: 1 descendant cleared2020: 1 descendant cleared2023: 1 descendant cleared2024: 2 descendants cleared2025: 1 descendant cleared2026: 1 descendant clearedK012727 · Humphrey OCT3 · Carl Zeiss Ophthalmic Systems, Inc. · 2002K030433 · Stratusoct with RNFL Normative Database · Carl Zeiss Meditec, Inc. · 2003 · recalledK033123 · Stratusoct with RNFL & Macula Normative Database · Carl Zeiss Meditec, Inc. · 2004 · recalledK063343 · Bioptigen Spectral Domain Ophthalmic Imaging System · Bioptigen, Inc. · 2006K071250 · CA, Model: Cam · Optovue, Inc. · 2007K101505 · Rtvue Model Rtvue 100 · Optovue, Inc. · 2010 · recalledK120238 · Rtvue XR Oct · Optovue, Inc. · 2012K153080 · RTVue XR OCT Avanti with AngioVue Software · Optovue, Inc. · 2016K181594 · Spectralis HRA+OCT and variants with OCT Angiography Module · Heidelberg Engineering GmbH · 2018 · recalled1995200020052010201520202025
Other ancestors, by generationDescendants, by generation 2 generations back: 1 other ancestor3 generations back: 1 other ancestor4 generations back: 2 other ancestors5 generations back: 2 other ancestors6 generations back: 5 other ancestors7 generations back: 5 other ancestors8 generations back: 1 other ancestor 1 generation forward: 1 descendant2 generations forward: 1 descendant3 generations forward: 1 descendant4 generations forward: 2 descendants5 generations forward: 2 descendants K181594 · Spectralis HRA+OCT and variants with OCT Angiography Module · Heidelberg Engineering GmbH · 2018 · recalledK153080 · RTVue XR OCT Avanti with AngioVue Software · Optovue, Inc. · 2016K120238 · Rtvue XR Oct · Optovue, Inc. · 2012K101505 · Rtvue Model Rtvue 100 · Optovue, Inc. · 2010 · recalledK071250 · CA, Model: Cam · Optovue, Inc. · 2007K063343 · Bioptigen Spectral Domain Ophthalmic Imaging System · Bioptigen, Inc. · 2006K033123 · Stratusoct with RNFL & Macula Normative Database · Carl Zeiss Meditec, Inc. · 2004 · recalledK030433 · Stratusoct with RNFL Normative Database · Carl Zeiss Meditec, Inc. · 2003 · recalledK012727 · Humphrey OCT3 · Carl Zeiss Ophthalmic Systems, Inc. · 2002−50+5
  1. Root · 9 generations backK012727 Humphrey OCT3Carl Zeiss Ophthalmic Systems, Inc. · 2002
  2. 5 generations between
  3. 3 generations backK120238 Rtvue XR OctOptovue, Inc. · 2012
  4. 2 generations backK153080 RTVue XR OCT Avanti with AngioVue SoftwareOptovue, Inc. · 2016
  5. 1 generation backK181594 Spectralis HRA+OCT and variants with OCT Angiography ModuleHeidelberg Engineering GmbH · 2018 · Recalled
  6. This deviceK182569 Spectralis HRA+OCT and variants with High Magnification ModuleHeidelberg Engineering GmbH · 2018
  7. Descendant · cites it directly · 6 of its ownK192391 Spectralis HRA+OCT and VariantsHeidelberg Engineering GmbH · 2019
  8. Descendant · 2 generations on · 5 of its ownK201252 Spectralis HRA+OCT and variantsHeidelberg Engineering GmbH · 2020
  9. Descendant · 3 generations on · 4 of its ownK223557 SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH · 2023
  10. Descendant · 4 generations on · 2 of its ownK240221 SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH · 2024
  11. Descendant · 5 generations on · 1 of its ownK250868 SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH · 2025
Show all 9 generations
  1. Root · 9 generations backK012727 Humphrey OCT3Carl Zeiss Ophthalmic Systems, Inc. · 2002
  2. 8 generations backK030433 Stratusoct with RNFL Normative DatabaseCarl Zeiss Meditec, Inc. · 2003 · Recalled
  3. 7 generations backK033123 Stratusoct with RNFL & Macula Normative DatabaseCarl Zeiss Meditec, Inc. · 2004 · Recalled
  4. 6 generations backK063343 Bioptigen Spectral Domain Ophthalmic Imaging SystemBioptigen, Inc. · 2006
  5. 5 generations backK071250 CA, Model: CamOptovue, Inc. · 2007
  6. 4 generations backK101505 Rtvue Model Rtvue 100Optovue, Inc. · 2010 · Recalled
  7. 3 generations backK120238 Rtvue XR OctOptovue, Inc. · 2012
  8. 2 generations backK153080 RTVue XR OCT Avanti with AngioVue SoftwareOptovue, Inc. · 2016
  9. 1 generation backK181594 Spectralis HRA+OCT and variants with OCT Angiography ModuleHeidelberg Engineering GmbH · 2018 · Recalled
  10. This deviceK182569 Spectralis HRA+OCT and variants with High Magnification ModuleHeidelberg Engineering GmbH · 2018

Showing 5 of 7 descendants. See all descendants

Descendants cleared per year

2019: 12020: 12023: 12024: 22025: 12026: 1
2019high 2 (2024) · low 0 (2021)2026

Most influential descendants

Showing 5 of 7 · See all
  • K192391Spectralis HRA+OCT and VariantsHeidelberg Engineering GmbH · 2019 · cites it directly6descendants
  • K201252Spectralis HRA+OCT and variantsHeidelberg Engineering GmbH · 2020 · 2 generations on5descendants
  • K223557SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH · 2023 · 3 generations on4descendants
  • K240221SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH · 2024 · 4 generations on2descendants
  • K250868SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH · 2025 · 5 generations on1descendant
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−9K012727Humphrey OCT3Carl Zeiss Ophthalmic Systems, Inc.2002—
−8K030433Stratusoct with RNFL Normative DatabaseCarl Zeiss Meditec, Inc.20031
−7K033123Stratusoct with RNFL & Macula Normative DatabaseCarl Zeiss Meditec, Inc.20041
−6K063343Bioptigen Spectral Domain Ophthalmic Imaging SystemBioptigen, Inc.2006—
−5K071250CA, Model: CamOptovue, Inc.2007—
−4K101505Rtvue Model Rtvue 100Optovue, Inc.20101
−3K120238Rtvue XR OctOptovue, Inc.2012—
−2K153080RTVue XR OCT Avanti with AngioVue SoftwareOptovue, Inc.2016—
−1K181594Spectralis HRA+OCT and variants with OCT Angiography ModuleHeidelberg Engineering GmbH20182
0 (this device)K182569Spectralis HRA+OCT and variants with High Magnification ModuleHeidelberg Engineering GmbH2018—
+1K192391Spectralis HRA+OCT and VariantsHeidelberg Engineering GmbH2019—
+2K201252Spectralis HRA+OCT and variantsHeidelberg Engineering GmbH2020—
+3K223557SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH2023—
+4K240221SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH2024—
+5K250868SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH2025—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199520
199810
200110
200220
200310
200420
200510
200630
201010
201210
201610
201710

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201910
202010
202310
202420
202510
202610
FIG. 1 — Lineage of K182569, 2002–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in OBO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new OBO device

  1. #1 K250868 SPECTRALIS HRA+OCT and variantsscore 16.2 · 14 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K181594Spectralis HRA+OCT and variants with OCT Angiography Module
Summary page 6
…with OCT Angiography Module Applicant: Heidelberg Engineering GmbH 510(k) Premarket Notification number: K181594 Classification: Class II CFR Title: 21 CFR 886.1570 FDA Product Co…
Heidelberg Engineering GmbH20182

What descends from it? (7)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K192391Spectralis HRA+OCT and VariantsHeidelberg Engineering GmbH20196

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 16 years and passes through 5 companies; a new generation was cleared every 1.5 years on median.
  • 4 of the 26 ancestors have a recall of any class.
  • Of its descendants, K192391 (Heidelberg Engineering GmbH, 2019) has gone furthest, with 6 descendants of its own.

How does its category compare?

All OBO devices

OBO Tomography, Optical Coherence: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · OBO

3in 2025

2007: 22008: 22009: 42010: 22011: 22012: 32013: 22014: 32015: 12016: 42017: 42018: 62019: 52020: 22021: 12022: 22023: 72024: 82025: 32026 (partial year): 2
2007high 8 (2024) · low 1 (2015)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · OBO

125in 2025

2009: 151 days median2012: 269 days median2014: 152 days median2016: 125 days median2017: 118 days median2018: 87 days median2019: 249 days median2023: 262 days median2024: 157 days median2025: 125 days median
2007high 269 (2012) · low 87 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · OBO

1in 2022

2010: 12011: 22012: 22018: 12021: 12022: 12026 (partial year): 1
2007high 2 (2011) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · OBO

4in 2025

2013: 22016: 12018: 12021: 12023: 32024: 32025: 4
2007high 4 (2025) · low 0 (2007)2025

MAUDE reports naming product code OBO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
2009415100
20102—10
20112—20
2012326920
20132—02
2014315200
20151—00
2016412501
2017411800
201868711
2019524900
20202—00
20211—11
20222—10
2023726203
2024815703
2025312504
20262—1—

What is it indicated for?

The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for: • viewing the posterior segment of the eye, including two- and three-dimensional imaging • cross-sectional imaging (SPECTRALIS HRA+OCT and SPECTRALIS OCT) • fundus imaging • fluorescence imaging (fluorescein angiography, indocyanine green angiography; SPECTRALIS HRA+OCT, SPECTRALIS HRA) • autofluorescence imaging (SPECTRALIS HRA+OCT, SPECTRALIS HRA and SPECTRALIS…

Read the full statement (242 words)

The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for:

• viewing the posterior segment of the eye, including two- and three-dimensional imaging

• cross-sectional imaging (SPECTRALIS HRA+OCT and SPECTRALIS OCT)

• fundus imaging

• fluorescence imaging (fluorescein angiography, indocyanine green angiography; SPECTRALIS HRA+OCT, SPECTRALIS HRA)

• autofluorescence imaging (SPECTRALIS HRA+OCT, SPECTRALIS HRA and SPECTRALIS OCT with BluePeak)

• performing measurements of ocular anatomy and ocular lesions.

The device is indicated as an aid in the detection and management of various ocular diseases, including:

• age-related macular degeneration

• macular edema

• diabetic retinopathy

• retinal and choroidal vascular diseases

• glaucoma

The device is indicated for viewing geographic atrophy.

The SPECTRALIS OCT Angiography Module is indicated as an aid in the visualization of vascular structures of the retina and choroid.

The SPECTRALIS HRA+OCT and SPECTRALIS OCT include the following reference databases:

• a retinal nerve fiber layer thickness reference database, which is used to quantitatively compare the retinal nerve fiber layer in the human retina to values of Caucasian normal subjects – the classification result being valid only for Caucasian subjects

• a reference database for retinal nerve fiber layer thickness and optic nerve head neuroretinal rim parameter measurements, which is used to quantitatively compare the retinal nerve fiber layer and neuroretinal rim in the human retina to values of normal subjects of different races and ethnicities representing the population mix of the USA (Glaucoma Module Premium Edition)

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K182569: Spectralis HRA+OCT and variants with High Magnification Module.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K182569

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026